Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 + MAPK Inhibitors in Radioiodine-Refractory Thyroid Cancer
NCT04544111Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of spartalizumab in thyroid cancer (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 1 year. Started Sep 2020; status: active, not recruiting.
02
Drugs
spartalizumab
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04544111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544111.